2种指标联合检测在卵巢癌早期诊断中的价值

目的探讨血清人附睾分泌蛋白4(HE4)和糖类抗原125(CA125)联合检测在卵巢癌早期诊断中的应用价值。方法选择95例卵巢肿瘤患者分为卵巢癌组(43例)和卵巢良性肿瘤组(52例),另选择同期健康体检者(30例)作为对照组。采用酶联免疫吸附试验(ELISA)检测各组患者血清中HE4水平,化学发光方法检测血清中CA125水平,比较血清HE4和CA125水平在各组患者中表达。结果血清HE4和CA125表达水平在卵巢癌组明显高于卵巢良性肿瘤组和对照组,差异有统计学意义(P0.05);卵巢癌Ⅲ~Ⅵ期患者血清HE4和CA125表达水平明显高于卵巢癌Ⅰ~Ⅱ期(P0.05)。HE4与CA125单独检测检出率较低,联合检测能提高检出率。结论血清HE4与CA125联合检测对卵巢癌早期检出率有重要的临床应用价值。

Value of combined detection of two indexes in early diagnosis of ovarian cancer

Objective To explore the application value of combined detection of human epididymis protein 4 (HE4)and CA125 in early diagnosis of ovarian cancer.Methods 95 cases of ovarian cancer were selected and divided into the ovarian cancer group(43 cases)and the benign ovarian tumor group(52 cases).Contemporaneous 30 healthy individuals of physical examination were selected as the control group.The level of HE4 was tested by ELISA and CA125 was tested by chemiluminescence.The results were compared among various groups.Results The levels of serum HE4 and CA125 in the ovarian cancer group was significantly higher those that in the benign ovarian tumor group and the control group,the difference was statistically significant(P < 0.05 ).The levels of serum HE4 and CA125 in the stage Ⅲ-Ⅵ of ovarian cancer were significantly higher than those in the stage Ⅰ-Ⅱ of ovarian canc-er(P <0.05).The single detection of HE4 and CA125 had lower detection rate and their combined detection could in-crease the detection rate.Conclusion The combined detection of HE4 and CA125 has an important application value for the early diagnosis of ovarian cancer.